Résumé :
|
[BDSP. Notice produite par INIST-CNRS qR0xFI97. Diffusion soumise à autorisation]. Aspirin use decreases colon cancer risk, but this association may vary among population subgroups. The aspirin-colon cancer association was evaluated according to body mass index and physical activity in 1,701 incident colon cancer cases diagnosed during follow-up of 139,310 participants for up to 26 years in 2 US prospective cohort studies that began in 1980 and 1992, respectively. Whether plasma C-peptide levels modified the association was examined by using a nested case-control design (n=384 cases, 749 controls). Multiplicative and additive interactions were tested. Body mass index did not modify the association ; pooled multivariable relative risks for regular aspirin use versus nonuse ranged from 0.74 to 0.75 in the normal weight and obese groups (test for multiplicative interaction, P=0.75 ; test for additive interaction, P=0.66). Pooled multivariable relative risks for regular aspirin use were 0.86 (95% confidence interval (CI) : 0.66,1.11) in the low and 0.67 (95% CI : 0.58,0.77) in the high physical activity groups with no interaction evident on either the multiplicative or additive scale (P>0.10). Plasma C-peptide levels also did not modify the aspirin-colon cancer association, with multivariable relative risks of 0.74 (95% CI : 0.50,1.10) for the low and 0.65 (95% CI : 0.46,0.92) for the high group. Reductions in colon cancer risk associated with aspirin use were not significantly modified by body mass index, physical activity, or plasma C-peptide level in this study.
|